文献速递肿瘤 PET/CT

「18F」AlF-RESCA-T4 的 Trop2 免疫 PET/CT 显像可区分肺癌与炎症

Immuno-PET/CT Imaging of Trop2 with [18F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation.
PubMed 文献 · J Nucl Med · 2024-12-03

研究在 CHO 细胞中重组表达两种 Trop2 单域抗体 T4 与 RT4,用 AlF-RESCA 法制备「18F」AlF-RESCA-T4 与「18F」AlF-RESCA-RT4,在荷瘤小鼠开展临床前显像与阻断研究,并开展一项初步临床试验评估「18F」AlF-RESCA-T4 免疫 PET/CT 的临床显像安全性与可行性;结果显示两种探针可特异性标注 Trop2 表达,临床「18F」AlF-RESCA-T4 免疫 PET/CT 可区分肺部炎症与肿瘤。

要点

  • 「18F」AlF-RESCA-T4 与「18F」AlF-RESCA-RT4 放射化学纯度高。
  • T3M-4 荷瘤小鼠中「18F」AlF-RESCA-T4 摄取 11.13 ± 1.53 %ID/g(n = 4),「18F」AlF-RESCA-RT4 为 8.83 ± 1.22 %ID/g(n = 4)。
  • 初步临床试验中「18F」AlF-RESCA-T4 免疫 PET/CT 可标注 Trop2 表达并区分肿瘤与结核等炎症性疾病。

核心结论

  • 「18F」AlF-RESCA-T4 与「18F」AlF-RESCA-RT4 可特异性标注 Trop2 表达。
  • 临床「18F」AlF-RESCA-T4 免疫 PET/CT 显像可筛选适合 Trop2 靶向治疗的患者,并可区分肺部炎症与癌症。

研究设计与样本

  • 研究在 CHO 细胞中重组表达两种 Trop2 单域抗体:带 His 标签的 T4 与无 His 标签的 RT4。
  • 用 SDS-PAGE、HPLC 与表面等离子体共振测定纯度与结合动力学,并以 AlF-RESCA 法制备「18F」AlF-RESCA-T4 与「18F」AlF-RESCA-RT4。
  • 在荷瘤小鼠开展临床前显像与阻断研究,并开展一项初步临床试验评估「18F」AlF-RESCA-T4 免疫 PET/CT 的临床显像安全性与可行性。

主要发现

  • 「18F」AlF-RESCA-T4 与「18F」AlF-RESCA-RT4 放射化学纯度高。
  • T3M-4 肿瘤模型中「18F」AlF-RESCA-T4 摄取为 11.13 ± 1.53 %ID/g(n = 4),「18F」AlF-RESCA-RT4 为 8.83 ± 1.22 %ID/g(n = 4);共注射未标记 T4 与 RT4 后摄取显著降低。
  • 去除 His 标签的策略进一步优化了探针体内药代动力学并降低肾脏放射性蓄积,且未显著降低肿瘤摄取。
  • 初步临床试验中「18F」AlF-RESCA-T4 免疫 PET/CT 在标注 Trop2 表达及区分肿瘤与结核等炎症性疾病方面显示出潜力。

临床怎么用

  • 作者认为临床「18F」AlF-RESCA-T4 免疫 PET/CT 显像可用于筛选适合 Trop2 靶向治疗的患者,并可区分肺部炎症与癌症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immuno-PET/CT imaging, a branch of molecular imaging, can noninvasively and specifically visualize biomarker expression across the body. Trophoblast cell surface antigen 2 (Trop2) is a pan-cancer biomarker and plays a crucial role in tumorigenesis through multiple signaling pathways. The study aims to develop and translate novel Trop2 single-domain antibody (sdAb) tracers for clinical use. Methods: Two sdAbs (i.e., His-tagged T4 and His-tag-free RT4) are recombinantly expressed in Chinese hamster ovary cells. The purities and binding kinetics are determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis, high-performance liquid chromatography, and surface plasmon resonance assays. The AlF restrained complexing agent (RESCA) method is applied to develop 18F-labeled sdAb tracers ([18F]AlF-RESCA-T4 and [18F]AlF-RESCA-RT4), followed by thorough preclinical imaging and blocking studies on tumor-bearing mice and a pilot clinical trial evaluating the clinical imaging safety and feasibility of [18F]AlF-RESCA-T4 immuno-PET/CT. Results: [18F]AlF-RESCA-T4 and [18F]AlF-RESCA-RT4 possess high radiochemical purities. Preclinical imaging in the T3M-4 tumor model revealed prominent uptake (percentage injected dose/g) of [18F]AlF-RESCA-T4 (11.13 ± 1.53, n = 4) and [18F]AlF-RESCA-RT4 (8.83 ± 1.22, n = 4), which were significantly reduced by coinjection of unlabeled T4 and RT4 in blocking studies. The His-tag removal strategy further optimized the probe's in vivo pharmacokinetics and reduced renal radioactivity accumulation without significantly decreasing tumor uptake. In a pilot clinical trial, [18F]AlF-RESCA-T4 immuno-PET/CT showed promising potency in annotating Trop2 expression and differentiating tumors from inflammatory diseases such as tuberculosis. Conclusion: [18F]AlF-RESCA-T4 and [18F]AlF-RESCA-RT4 can specifically annotate Trop2 expression. Clinical [18F]AlF-RESCA-T4 immuno-PET/CT imaging can screen patients for Trop2-targeted therapies and differentiate lung inflammation from cancer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Huang W, Cao M, Wu Y, et al. Immuno-PET/CT Imaging of Trop2 with [18F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation. J Nucl Med. 2024. PMID: 39542697. doi:10.2967/jnumed.124.268751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。